Milestone Scientific (MLSS) AI Stock Analysis

• Market Cap: $23.06M
• Dividend Yield: N/A
• Average Volume (3M): 172.66K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.71
• Revenue Growth: 0.59%
• EPS Growth: -39.76%
• Country: US
• Employees: 17
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Instruments & Supplies
• EPS (TTM): -0.01
• Shares Outstanding: 78,628,914
• 10 Day Avg. Volume: 233,274
• 30 Day Avg. Volume: 172,658
• PEG Ratio: 0.43
• Price to Book (P/B): 13.13
• Price to Sales (P/S): 8.88
• P/FCF Ratio: -26.14
• Enterprise Value/Market Cap: 2.26
• Enterprise Value/Revenue: 5.73
• Enterprise Value/Gross Profit: 7.87
• Enterprise Value/Ebitda: -7.59
• 1Y Price Target: $1.00
• Price Target Upside: 244.83% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 42 Neutral
• Price Target: $0.28 ▼(-3.79% Downside)

The score is held down primarily by weak financial performance (large losses and negative cash flow) and bearish technicals (below key moving averages with negative MACD). Valuation offers limited support due to a negative P/E and no dividend, while the earnings call provided only moderate positives via cost reductions and reimbursement progress amid continued commercial execution risks and listing-compliance overhang.

Positive Factors

Cost Management

Effective cost management and operational restructuring can enhance profitability and support long-term financial health.

Medicare Payment Progress

Securing Medicare payment rates can drive adoption and revenue growth in the medical segment, strengthening market position.

Shareholder Support

Increased authorized shares provide capital flexibility for growth initiatives, reflecting shareholder confidence in strategic direction.

Negative Factors

Negative Cash Flow

Negative cash flow indicates challenges in sustaining operations and funding growth, impacting long-term financial stability.

Domestic Revenue Decline

Declining domestic revenue suggests difficulties in maintaining market share and could hinder overall growth prospects.

NYSE Non-Compliance

Non-compliance with NYSE standards poses a risk of delisting, which could affect investor confidence and access to capital.

Milestone Scientific Business Overview & Revenue Model

Company Description

Milestone Scientific Inc. designs, develops, and commercializes diagnostic and therapeutic injection technologies, and devices for medical, dental, and cosmetic use in the United States, China, and internationally. The company operates in two segments, Dental and Medical. Its products include CompuDent and STA Single Tooth Anesthesia System that are used for all dental procedures that require local anesthetic. The company also offers CompuFlo, a computer-controlled drug delivery system for the painless delivery of drugs, anesthetics, and other medicaments, as well as for the aspiration of bodily fluids or previously injected substances; and disposable injection handpiece for the tactile control during the injection. In addition, it provides CompuFlo Epidural, a computer controlled anesthesia system for use in various medical applications. Further, the company offers CompuMed for use in various medical procedures performed in plastic, hair restoration, and colorectal surgery, as well as podiatry, dermatology, orthopedics, and various other disciplines. Milestone Scientific Inc. was incorporated in 1989 and is headquartered in Livingston, New Jersey.

How the Company Makes Money

Milestone Scientific generates revenue primarily through the sale of its proprietary injection technology systems and disposable products. Key revenue streams include direct sales of the CompuFlo® and Wand® systems to dental and medical practitioners, as well as recurring revenue from disposable cartridges and accessories required for these systems. Additionally, the company may engage in strategic partnerships with healthcare providers and distributors to expand its market reach. Factors contributing to its earnings include the growing demand for pain management solutions in medical and dental procedures, as well as potential licensing agreements for its technology.

Milestone Scientific Financial Statement Overview

Summary

Milestone Scientific faces significant financial challenges. Despite a strong gross profit margin, the company operates at a loss with negative net profit and cash flow margins. The balance sheet shows low leverage but a concerning negative return on equity. Overall, financial health is weak, necessitating operational improvements.

Income Statement

Milestone Scientific's income statement reveals a challenging financial position. The company has experienced a slight revenue growth of 5.45% in the TTM period, but it continues to operate at a loss with a negative net profit margin of -61.16%. The gross profit margin is relatively strong at 74.37%, indicating efficient cost management in production. However, the negative EBIT and EBITDA margins highlight ongoing operational inefficiencies and high operating expenses.

Balance Sheet

The balance sheet shows a low debt-to-equity ratio of 0.07, suggesting a conservative approach to leveraging. However, the return on equity is negative at -82.73%, indicating that the company is not generating sufficient returns on shareholders' investments. The equity ratio stands at 41.48%, reflecting a moderate level of financial stability, but the overall negative ROE is a significant concern.

Cash Flow

Cash flow analysis indicates significant challenges, with a negative operating cash flow and free cash flow. The free cash flow growth rate is positive at 93.82%, but this is from a negative base, indicating volatility. The operating cash flow to net income ratio is negative, suggesting that the company struggles to convert its accounting profits into cash. The free cash flow to net income ratio is slightly above 1, indicating that free cash flow is in line with net income, albeit both are negative.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	9.08M	8.63M	9.83M	8.81M	10.30M	5.44M
Gross Profit	6.61M	6.43M	6.79M	4.90M	6.31M	3.62M
EBITDA	-6.86M	-6.72M	-7.04M	-8.76M	-7.30M	-7.36M
Net Income	-6.97M	-4.71M	-6.93M	-8.71M	-6.82M	-7.34M
Balance Sheet
Total Assets	8.05M	9.80M	11.37M	13.70M	19.81M	19.57M
Cash, Cash Equivalents and Short-Term Investments	1.27M	3.26M	5.95M	8.72M	14.76M	14.22M
Total Debt	1.09M	349.05K	395.98K	497.04K	586.59K	942.60K
Total Liabilities	4.71M	3.96M	3.36M	3.70M	3.59M	3.46M
Stockholders Equity	3.34M	5.83M	8.01M	10.23M	16.37M	16.20M
Cash Flow
Free Cash Flow	-5.26M	-2.93M	-5.33M	-6.04M	-4.03M	-7.01M
Operating Cash Flow	-5.26M	-2.92M	-5.33M	-6.03M	-4.02M	-6.98M
Investing Cash Flow	-2.98M	2.97M	-2.97M	-8.53K	-15.19K	-21.44K
Financing Cash Flow	789.19K	233.77K	2.56M	-8.54K	4.57M	19.71M

Milestone Scientific Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.29
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MLSS, the sentiment is Negative. The current price of 0.29 is below the 20-day moving average (MA) of 0.30, below the 50-day MA of 0.33, and below the 200-day MA of 0.61, indicating a bearish trend. The MACD of -0.02 indicates Negative momentum. The RSI at 40.88 is Neutral, neither overbought nor oversold. The STOCH value of 67.18 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for MLSS.

Milestone Scientific Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
NEPH	69 Neutral	$48.25M	32.01	16.29%	―	32.36%	―
POCI	52 Neutral	$32.25M	-5.00	-57.98%	―	13.67%	-37.01%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
NXGL	51 Neutral	$18.13M	-4.41	-58.34%	―	73.38%	34.87%
RVP	48 Neutral	$22.60M	-3.32	-8.05%	―	-0.95%	58.17%
FEMY	45 Neutral	$35.39M	-0.81	-376.23%	―	63.53%	12.49%
MLSS	42 Neutral	$23.06M	-3.46	-136.47%	―	0.59%	-39.76%

Milestone Scientific Corporate Events

Milestone Scientific Shareholders Approve Governance and Share Increase

Milestone Scientific Inc. held its 2024 Annual Meeting of Stockholders on December 18, 2025, with 61.53% of its 78,628,913 outstanding common shares represented in the vote. Shareholders re-elected six incumbent directors, approved an increase in authorized common shares from 100 million to 125 million, and ratified CBIZCPA P.C. as the independent auditors for the fiscal year ending December 31, 2025, underscoring strong shareholder support for current leadership, expanded capital flexibility, and the company’s chosen auditing firm.

The most recent analyst rating on (MLSS) stock is a Hold with a $0.33 price target. To see the full list of analyst forecasts on Milestone Scientific stock, see the MLSS Stock Forecast page.

Milestone Scientific Director Leonard Osser Resigns

On November 7, 2025, Leonard A. Osser resigned as a director of Milestone Scientific Inc., but will continue his involvement through an employment and consulting agreement. This change in leadership may impact the company’s operations and stakeholder relations, as Mr. Osser remains connected to the company in a different capacity.

The most recent analyst rating on (MLSS) stock is a Sell with a $0.50 price target. To see the full list of analyst forecasts on Milestone Scientific stock, see the MLSS Stock Forecast page.

Milestone Scientific Faces NYSE Non-Compliance Notice

On October 8, 2025, Milestone Scientific Inc. received a notice from NYSE American LLC indicating non-compliance with certain listing standards. The company must submit a compliance plan by November 7, 2025, to maintain its listing, with potential delisting if standards are not met by April 8, 2027.

The most recent analyst rating on (MLSS) stock is a Buy with a $1.25 price target. To see the full list of analyst forecasts on Milestone Scientific stock, see the MLSS Stock Forecast page.